Navigation Links
AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results
Date:2/5/2008

WEST CHESTER, Ohio, Feb. 5 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation products, will release its financial results for the fourth quarter and full year ended December 31, 2007 on Thursday, February 14, 2008.

AtriCure will host a conference call at 10:00 a.m. ET on Thursday, February 14, 2008 to discuss fourth quarter and full year 2007 results. A live web cast of the conference call will be available online from the investor relations page of AtriCure's corporate web site at http://www.atricure.com.
Pre-registration is available for this call at the following URL:

https://www.theconferencingservice.com/prereg/key.process?key=PQ8Q3WXJN

Pre-registering is not mandatory but is recommended as it will provide you immediate entry into the call and will facilitate the timely start of the conference. Pre-registration only takes a few moments and you may pre-register at any time, including up to and after the call start time. Alternatively, if you prefer being placed into the call by an operator, please call (888) 713- 4214 for domestic callers and (617) 213-4866 for international callers at least 15 minutes prior to the call start time and use reservation number 25413911.

The web cast will remain available on AtriCure's web site through March 15, 2008. A telephonic replay of the call will also be available until March 15, 2008. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Please use reservation code 60682842.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 2.5 million Americans and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) bipolar ablation system, including the new Isolator Synergy(TM) ablation clamps and the AtriCure multifunctional bipolar Pen, for the ablation, or destruction, of cardiac tissues during surgical procedures. Additionally, the FDA has cleared the AtriCure Pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF. AtriCure's left atrial appendage clip system has not been approved for commercial use. It is currently being used in clinical evaluations in Europe.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com


'/>"/>
SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at BMO Capital Markets 2007 Healthcare Conference
2. AtriCure Reports Third Quarter 2007 Financial Results
3. AtriCure Ranked 80th in Deloittes Technology Fast 500
4. AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results
5. Published Results Using AtriCure Minimally Invasive Products
6. AtriCure to Present at ThinkEquity Partners 5th Annual Growth Conference
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. AtriCure to Present at Roth Capital Partners 2007 New York Conference
9. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
10. California Department of Social Services Announces Improved Access to Disability Payments to Homeless Individuals
11. LOreal USA Announces Three-Year Support of Womens Dermatologic Society Foundation Community Outreach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market leader in ... by Eastside Partners, with participation from existing investor Martin Ventures. The funds ... its technology and product roadmap. , “Jvion is experiencing significant growth ...
(Date:4/29/2016)... Beach, CA (PRWEB) , ... April 29, 2016 , ... ... Jane L. Frederick, Dr. Sanaz Ghazal, and Dr. Daniel A. Potter -- are proud ... Society for Assisted Reproductive Technology (SART). In April, SART published the latest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... software, outsourced billing and coding services, and Deyta Analytics, recently announced the recipients ... the highest level of quality as measured from the caregiver’s point of view. ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... clinic data for 2014. Each year, reproductive endocrinologists are required to report ... the main organization of professionals dedicated to the practice of assisted reproductive technologies ...
(Date:4/29/2016)... ... , ... In its efforts of bringing quality senior care and expanding reach ... expansion as it welcomes Ferdie Vasquez of the new 1Heart Caregiver Services Las Vegas ... of working in various industries. He had been a Franchise owner of a ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... PARIS , April 29, 2016 ... Jérôme Contamine, Directeur Financier ... la santé, publie ses résultats pour ... Financier du Groupe, Jérôme Contamine, commente ... Groupe et les perspectives pour le ...
(Date:4/28/2016)... April 28, 2016 Research and ... Plastic Surgery Products Market 2016-2020" report to their ... , The global plastic surgery products market ... during the period 2016-2020. , ,The growing adoption of ... the growth of the market. Lasers are used to ...
(Date:4/28/2016)... Net Sales of $1.90 billion represent an increase of 67.8% ... an increase of 1.2% on an adjusted pro forma, constant ... were $0.52 reported, a decrease of 47.5% from the prior ... the prior year period , The Company increases constant ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported ...
Breaking Medicine Technology: